{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:35:12Z","timestamp":1787578512515,"version":"build-2736575974"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":126,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02646-1","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:26:12Z","timestamp":1776680772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas"],"prefix":"10.1186","volume":"25","author":[{"given":"Jon","family":"Celay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Recalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Revuelta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Larrayoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Garcia-Lacarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00f1at","family":"Ariceta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Garcia-Barchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Fresquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalen","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Qing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Roncador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaira","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Roccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Knittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Herter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Goodhew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus San","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Canales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Lasarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Cerchietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Martinez-Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"2646_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBdeO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"key":"2646_CR2","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood.2022015854","volume":"140","author":"L de Leval","year":"2022","unstructured":"de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022;140:2193\u2013227. https:\/\/doi.org\/10.1182\/blood.2022015854.","journal-title":"Blood"},{"key":"2646_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3322\/canjclin.47.6.351","volume":"47","author":"AT Skarin","year":"1997","unstructured":"Skarin AT, Dorfman DM. Non-Hodgkin\u2019s lymphomas: current classification and management. CA Cancer J Clin. 1997;47:351\u201372. https:\/\/doi.org\/10.3322\/canjclin.47.6.351.","journal-title":"CA Cancer J Clin"},{"key":"2646_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32407-2","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017. https:\/\/doi.org\/10.1016\/S0140-6736(16)32407-2.","journal-title":"Lancet"},{"key":"2646_CR5","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842\u201358. https:\/\/doi.org\/10.1056\/NEJMra2027612.","journal-title":"N Engl J Med"},{"key":"2646_CR6","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMra2102568","volume":"386","author":"D Rossi","year":"2022","unstructured":"Rossi D, Bertoni F, Zucca E. Marginal-zone lymphomas. N Engl J Med. 2022;386:568\u201381. https:\/\/doi.org\/10.1056\/NEJMra2102568.","journal-title":"N Engl J Med"},{"key":"2646_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1182\/hematology.2020000121","volume":"2020","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Treon SP. Management of Waldenstr\u00f6m macroglobulinemia in 2020. Hematol Am Soc Hematol Educ Program. 2020;2020:372\u20139. https:\/\/doi.org\/10.1182\/hematology.2020000121.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2646_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14:517\u201334. https:\/\/doi.org\/10.1038\/nrc3774.","journal-title":"Nat Rev Cancer"},{"key":"2646_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019240","author":"A Sacco","year":"2023","unstructured":"Sacco A, Desantis V, Celay J, Giustini V, Rigali F, Savino FD, et al. Targeting the immune microenvironment in Waldenstr\u00f6m Macroglobulinemia via halting the CD40\/CD40-ligand axis. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2022019240.","journal-title":"Blood"},{"key":"2646_CR10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41556-020-0532-x","volume":"22","author":"T Roider","year":"2020","unstructured":"Roider T, Seufert J, Uvarovskii A, Frauhammer F, Bordas M, Abedpour N, et al. Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels. Nat Cell Biol. 2020;22:896\u2013906. https:\/\/doi.org\/10.1038\/s41556-020-0532-x.","journal-title":"Nat Cell Biol"},{"key":"2646_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2643-3230.BCD-21-0075","volume":"3","author":"G Han","year":"2022","unstructured":"Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, et al. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov. 2022;3:428\u201343. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0075.","journal-title":"Blood Cancer Discov"},{"key":"2646_CR12","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1182\/blood.2020009855","volume":"137","author":"S Haebe","year":"2021","unstructured":"Haebe S, Shree T, Sathe A, Day G, Czerwinski DK, Grimes SM, et al. Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. Blood. 2021;137:2869\u201380. https:\/\/doi.org\/10.1182\/blood.2020009855.","journal-title":"Blood"},{"key":"2646_CR13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0839","author":"N Kotlov","year":"2021","unstructured":"Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 2021. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0839.","journal-title":"Cancer Discov"},{"key":"2646_CR14","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","volume":"39","author":"CB Steen","year":"2021","unstructured":"Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell. 2021;39:1422-1437.e10. https:\/\/doi.org\/10.1016\/j.ccell.2021.08.011.","journal-title":"Cancer Cell"},{"key":"2646_CR15","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","volume":"41","author":"M-C Zhang","year":"2023","unstructured":"Zhang M-C, Tian S, Fu D, Wang L, Cheng S, Yi H-M, et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial. Cancer Cell. 2023;41:1705-1716.e5. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.004.","journal-title":"Cancer Cell"},{"key":"2646_CR16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P Somatic Mutation in Waldenstr\u00f6m\u2019s Macroglobulinemia. N Engl J Med. 2012;367:826\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1200710.","journal-title":"N Engl J Med"},{"key":"2646_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1365-2141.2012.09176.x","volume":"158","author":"Z-M Li","year":"2012","unstructured":"Li Z-M, Rinaldi A, Cavalli A, Mensah AA, Ponzoni M, Gascoyne RD, et al. MYD88 somatic mutations in MALT lymphomas. Br J Haematol. 2012;158:662\u20134. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09176.x.","journal-title":"Br J Haematol"},{"key":"2646_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K-H, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115\u20139. https:\/\/doi.org\/10.1038\/nature09671.","journal-title":"Nature"},{"key":"2646_CR19","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa1801445.","journal-title":"N Engl J Med"},{"key":"2646_CR20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390. https:\/\/doi.org\/10.1038\/s41591-018-0016-8.","journal-title":"Nat Med"},{"key":"2646_CR21","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/blood-2015-11-684183","volume":"127","author":"G Knittel","year":"2016","unstructured":"Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, et al. B-cell\u2013specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Blood. 2016;127:2732\u201341. https:\/\/doi.org\/10.1182\/blood-2015-11-684183.","journal-title":"Blood"},{"key":"2646_CR22","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1182\/blood.2020004918","volume":"137","author":"X Yu","year":"2021","unstructured":"Yu X, Li W, Deng Q, Liu H, Wang X, Hu H, et al. MYD88 L265P elicits mutation-specific ubiquitination to drive NF-\u03baB activation and lymphomagenesis. Blood. 2021;137:1615\u201327. https:\/\/doi.org\/10.1182\/blood.2020004918.","journal-title":"Blood"},{"key":"2646_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551-568.e14. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015.","journal-title":"Cancer Cell"},{"key":"2646_CR24","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-15-1525","volume":"22","author":"J Rovira","year":"2016","unstructured":"Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, et al. MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. Clin Cancer Res. 2016;22:2755\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1525.","journal-title":"Clin Cancer Res"},{"key":"2646_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3324\/haematol.2018.214122","volume":"105","author":"JS Vermaat","year":"2020","unstructured":"Vermaat JS, Somers SF, de Wree LC, Kraan W, de Groen RAL, Schrader AMR, et al. MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica. 2020;105:424\u201334. https:\/\/doi.org\/10.3324\/haematol.2018.214122.","journal-title":"Haematologica"},{"key":"2646_CR26","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020;135:1759\u201371. https:\/\/doi.org\/10.1182\/blood.2019003535.","journal-title":"Blood"},{"key":"2646_CR27","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1182\/blood-2002-10-3236","volume":"101","author":"D Sanchez-Izquierdo","year":"2003","unstructured":"Sanchez-Izquierdo D. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood. 2003;101:4539\u201346. https:\/\/doi.org\/10.1182\/blood-2002-10-3236.","journal-title":"Blood"},{"key":"2646_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl4644","author":"S Rodriguez","year":"2022","unstructured":"Rodriguez S, Celay J, Goicoechea I, Jimenez C, Botta C, Garcia-Barchino M-J, et al. Preneoplastic somatic mutations including MYD88 L265P in lymphoplasmacytic lymphoma. Sci Adv. 2022. https:\/\/doi.org\/10.1126\/sciadv.abl4644.","journal-title":"Sci Adv"},{"key":"2646_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nri3814","volume":"15","author":"K Basso","year":"2015","unstructured":"Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015;15:172\u201384. https:\/\/doi.org\/10.1038\/nri3814.","journal-title":"Nat Rev Immunol"},{"key":"2646_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cell.2020.05.049","volume":"182","author":"L Venturutti","year":"2020","unstructured":"Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, et al. TBL1XR1 mutations drive extranodal lymphoma by inducing a pro-tumorigenic memory fate. Cell. 2020;182:297-316.e27. https:\/\/doi.org\/10.1016\/j.cell.2020.05.049.","journal-title":"Cell"},{"key":"2646_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.beha.2016.09.002","volume":"30","author":"M-Q Du","year":"2017","unstructured":"Du M-Q. Malt lymphoma: genetic abnormalities, immunological stimulation and molecular mechanism. Best Pract Res Clin Haematol. 2017;30:13\u201323. https:\/\/doi.org\/10.1016\/j.beha.2016.09.002.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2646_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.024","author":"DP Calado","year":"2010","unstructured":"Calado DP, Zhang B, Srinivasan L, Sasaki Y, Seagal J, Unitt C, et al. Constitutive canonical NF-\u03baB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell. 2010. https:\/\/doi.org\/10.1016\/j.ccr.2010.11.024.","journal-title":"Cancer Cell"},{"key":"2646_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ajh.25446","volume":"94","author":"JP Alderuccio","year":"2019","unstructured":"Alderuccio JP, Zhao W, Desai A, Ramdial J, Gallastegui N, Kimble E, et al. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. Am J Hematol. 2019;94:585\u201396. https:\/\/doi.org\/10.1002\/ajh.25446.","journal-title":"Am J Hematol"},{"key":"2646_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91\u2013103. https:\/\/doi.org\/10.1016\/S1470-2045(21)00591-X.","journal-title":"Lancet Oncol"},{"key":"2646_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.21.02143","volume":"40","author":"R Shouval","year":"2022","unstructured":"Shouval R, Alarcon Tomas A, Fein JA, Flynn JR, Markovits E, Mayer S, et al. Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy. J Clin Oncol. 2022;40:369\u201381. https:\/\/doi.org\/10.1200\/JCO.21.02143.","journal-title":"J Clin Oncol"},{"key":"2646_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093933","author":"E Traggiai","year":"2004","unstructured":"Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti J-C, Lanzavecchia A, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004. https:\/\/doi.org\/10.1126\/science.1093933.","journal-title":"Science"},{"key":"2646_CR37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","volume":"18","author":"JA Burger","year":"2018","unstructured":"Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18:148\u201367. https:\/\/doi.org\/10.1038\/nrc.2017.121.","journal-title":"Nat Rev Cancer"},{"key":"2646_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert M, Klinger B, Kl\u00fcnemann M, Sieber A, Uhlitz F, Sauer S, et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun. 2018;9:20. https:\/\/doi.org\/10.1038\/s41467-017-02391-6.","journal-title":"Nat Commun"},{"key":"2646_CR39","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri3084","volume":"11","author":"J Neefjes","year":"2011","unstructured":"Neefjes J, Jongsma MLM, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11:823\u201336. https:\/\/doi.org\/10.1038\/nri3084.","journal-title":"Nat Rev Immunol"},{"key":"2646_CR40","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu W, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120:3986\u201396. https:\/\/doi.org\/10.1182\/blood-2012-05-433334.","journal-title":"Blood"},{"key":"2646_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2003533","author":"K Stirm","year":"2021","unstructured":"Stirm K, Leary P, Bertram K, N\u00fa\u00f1ez NG, W\u00fcst D, Boudesco C, et al. Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma. Oncoimmunology. 2021. https:\/\/doi.org\/10.1080\/2162402X.2021.2003533.","journal-title":"Oncoimmunology"},{"key":"2646_CR42","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/blood.2024025755","volume":"145","author":"M Garcia-Lacarte","year":"2025","unstructured":"Garcia-Lacarte M, Grijalba SC, Melchor J, Pascual M, Go\u00f1i E, Clemente-Larramendi I, et al. IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy. Blood. 2025;145:2746\u201361. https:\/\/doi.org\/10.1182\/blood.2024025755.","journal-title":"Blood"},{"key":"2646_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan C-H, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12:1088. https:\/\/doi.org\/10.1038\/s41467-021-21246-9.","journal-title":"Nat Commun"},{"key":"2646_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5989","author":"C Claus","year":"2019","unstructured":"Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aav5989.","journal-title":"Sci Transl Med"},{"key":"2646_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","volume":"610","author":"L Codarri Deak","year":"2022","unstructured":"Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature. 2022;610:161\u201372. https:\/\/doi.org\/10.1038\/s41586-022-05192-0.","journal-title":"Nature"},{"key":"2646_CR46","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","volume":"27","author":"A Niroula","year":"2021","unstructured":"Niroula A, Sekar A, Murakami MA, Trinder M, Agrawal M, Wong WJ, et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021;27:1921\u20137. https:\/\/doi.org\/10.1038\/s41591-021-01521-4.","journal-title":"Nat Med"},{"key":"2646_CR47","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1038\/s41588-023-01555-z","volume":"55","author":"SN Stacey","year":"2023","unstructured":"Stacey SN, Zink F, Halldorsson GH, Stefansdottir L, Gudjonsson SA, Einarsson G, et al. Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis. Nat Genet. 2023;55:2149\u201359. https:\/\/doi.org\/10.1038\/s41588-023-01555-z.","journal-title":"Nat Genet"},{"key":"2646_CR48","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2019000588","volume":"3","author":"T Sewastianik","year":"2019","unstructured":"Sewastianik T, Guerrera ML, Adler K, Dennis PS, Wright K, Shanmugam V, et al. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Adv. 2019;3:3360\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2019000588.","journal-title":"Blood Adv"},{"key":"2646_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641692","author":"C Ouk","year":"2021","unstructured":"Ouk C, Roland L, Gachard N, Poulain S, Oblet C, Rizzo D, et al. Continuous MYD88 activation is associated with expansion and then transformation of IgM differentiating plasma cells. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.641692.","journal-title":"Front Immunol"},{"key":"2646_CR50","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.2022015926","volume":"140","author":"GM Pindzola","year":"2022","unstructured":"Pindzola GM, Razzaghi R, Tavory RN, Nguyen HT, Morris VM, Li M, et al. Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma. Blood. 2022;140:1119\u201331. https:\/\/doi.org\/10.1182\/blood.2022015926.","journal-title":"Blood"},{"key":"2646_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.602868","volume":"11","author":"K Schmidt","year":"2020","unstructured":"Schmidt K, Sack U, Graf R, Winkler W, Popp O, Mertins P, et al. B-cell-specific Myd88 L252P expression causes a premalignant gammopathy resembling IgM MGUS. Front Immunol. 2020;11:1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2020.602868.","journal-title":"Front Immunol"},{"key":"2646_CR52","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1182\/BLOODADVANCES.2023011213","volume":"8","author":"R Fl\u00fcmann","year":"2024","unstructured":"Fl\u00fcmann R, Hansen J, Meinel J, Pfeiffer P, Wittkopf HG, L\u00fctz A, et al. An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma. Blood Adv Blood Adv. 2024;8:1063\u201374. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2023011213.","journal-title":"Blood Adv Blood Adv"},{"key":"2646_CR53","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1182\/BLOOD.2020005244","volume":"137","author":"M Reimann","year":"2021","unstructured":"Reimann M, Schrezenmeier J, Richter-Pechanska P, Dolnik A, Hick TP, Schleich K, et al. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. Blood Blood. 2021;137:2785\u201399. https:\/\/doi.org\/10.1182\/BLOOD.2020005244.","journal-title":"Blood Blood"},{"key":"2646_CR54","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1084\/JEM.20161454","volume":"214","author":"JQ Wang","year":"2017","unstructured":"Wang JQ, Jeelall YS, Humburg P, Batchelor EL, Kaya SM, Yoo HM, et al. Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM. J Exp Med J Exp Med. 2017;214:2759\u201376. https:\/\/doi.org\/10.1084\/JEM.20161454.","journal-title":"J Exp Med J Exp Med"},{"key":"2646_CR55","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/annonc\/mdl109","volume":"17","author":"O Tournilhac","year":"2006","unstructured":"Tournilhac O, Santos DD, Xu L, Kutok J, Tai Y-T, Le Gouill S, et al. Mast cells in Waldenstrom\u2019s macroglobulinemia support lymphoplasmacytic cell growth through CD154\/CD40 signaling. Ann Oncol. 2006;17:1275\u201382. https:\/\/doi.org\/10.1093\/annonc\/mdl109.","journal-title":"Ann Oncol"},{"key":"2646_CR56","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/2643-3230.BCD-21-0043","volume":"2","author":"A Kaushal","year":"2021","unstructured":"Kaushal A, Nooka AK, Carr AR, Pendleton KE, Barwick BG, Manalo J, et al. Aberrant extrafollicular B cells, immune dysfunction, myeloid inflammation, and MyD88-mutant progenitors precede Waldenstrom macroglobulinemia. Blood Cancer Discov. 2021;2:600\u201315. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0043.","journal-title":"Blood Cancer Discov"},{"key":"2646_CR57","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/leu.2010.76","volume":"24","author":"VJ Craig","year":"2010","unstructured":"Craig VJ, Cogliatti SB, Arnold I, Gerke C, Balandat J-E, W\u00fcndisch T, et al. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia. 2010;24:1186\u201396. https:\/\/doi.org\/10.1038\/leu.2010.76.","journal-title":"Leukemia"},{"key":"2646_CR58","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41563-023-01495-3","volume":"22","author":"SB Shah","year":"2023","unstructured":"Shah SB, Carlson CR, Lai K, Zhong Z, Marsico G, Lee KM, et al. Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas. Nat Mater. 2023;22:511\u201323. https:\/\/doi.org\/10.1038\/s41563-023-01495-3.","journal-title":"Nat Mater"},{"key":"2646_CR59","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1126\/science.1090769","volume":"302","author":"AA Ruefli-Brasse","year":"2003","unstructured":"Ruefli-Brasse AA, French DM, Dixit VM. Regulation of NF-\u03baB-dependent lymphocyte activation and development by paracaspase. Science (1979). 2003;302:1581\u20134. https:\/\/doi.org\/10.1126\/science.1090769.","journal-title":"Science (1979)"},{"key":"2646_CR60","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2206913.","journal-title":"N Engl J Med"},{"key":"2646_CR61","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","volume":"3","author":"V Dufner","year":"2019","unstructured":"Dufner V, Sayehli CM, Chatterjee M, Hummel HD, Gelbrich G, Bargou RC, et al. Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Adv. 2019;3:2491\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2019000025.","journal-title":"Blood Adv"},{"key":"2646_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1082","author":"J Wei","year":"2022","unstructured":"Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Olson K, Rizvi S, et al. CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models. Sci Transl Med. 2022. https:\/\/doi.org\/10.1126\/scitranslmed.abn1082.","journal-title":"Sci Transl Med"},{"key":"2646_CR63","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2022-156808","volume":"140","author":"M Dickinson","year":"2022","unstructured":"Dickinson M, Gritti G, Carlo-Stella C, Walter HS, Carlile D, Getzmann N, et al. Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed\/Refractory B Cell Lymphoma. Blood. 2022;140:3818\u201320. https:\/\/doi.org\/10.1182\/blood-2022-156808.","journal-title":"Blood"},{"key":"2646_CR64","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23:1066\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(22)00339-4.","journal-title":"Lancet Oncol"},{"key":"2646_CR65","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2115304.","journal-title":"N Engl J Med"},{"key":"2646_CR66","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1182\/blood-2023-180231","volume":"142","author":"M Kaplan","year":"2023","unstructured":"Kaplan M, Basavanhally T, Nakayama Y, Kyriakopoulos C, Amzallag A, Gkasiamis A, et al. Pharmacodynamic biomarkers and CtDNA support the mechanism of action and clinical efficacy of golcadomide (CC-99282) combined with R-CHOP in previously untreated aggressive B-cell lymphoma. Blood. 2023;142:1631\u20131631. https:\/\/doi.org\/10.1182\/blood-2023-180231.","journal-title":"Blood"},{"key":"2646_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50830-y","volume":"15","author":"ME Stokes","year":"2024","unstructured":"Stokes ME, Wenzl K, Huang CC, Ortiz M, Hsu C-C, Maurer MJ, et al. Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation. Nat Commun. 2024;15:6790. https:\/\/doi.org\/10.1038\/s41467-024-50830-y.","journal-title":"Nat Commun"},{"key":"2646_CR68","doi-asserted-by":"publisher","DOI":"10.1101\/gad.14.8.994","author":"S Marino","year":"2000","unstructured":"Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000. https:\/\/doi.org\/10.1101\/gad.14.8.994.","journal-title":"Genes Dev"},{"key":"2646_CR69","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1074-7613(03)00267-X","volume":"19","author":"M Shapiro-Shelef","year":"2003","unstructured":"Shapiro-Shelef M, Lin K-I, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity. 2003;19:607\u201320. https:\/\/doi.org\/10.1016\/S1074-7613(03)00267-X.","journal-title":"Immunity"},{"key":"2646_CR70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.19.8661","author":"A Strasser","year":"1991","unstructured":"Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A. 1991. https:\/\/doi.org\/10.1073\/pnas.88.19.8661.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2646_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11889","author":"EF Robles","year":"2016","unstructured":"Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du M-Q, et al. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nat Commun. 2016. https:\/\/doi.org\/10.1038\/ncomms11889.","journal-title":"Nat Commun"},{"key":"2646_CR72","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1073\/pnas.0602353103","volume":"103","author":"S Casola","year":"2006","unstructured":"Casola S, Cattoretti G, Uyttersprot N, Koralov SB, Segal J, Hao Z, et al. Tracking germinal center B cells expressing germ-line immunoglobulin 1 transcripts by conditional gene targeting. Proc Natl Acad Sci U S A. 2006;103:7396\u2013401. https:\/\/doi.org\/10.1073\/pnas.0602353103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2646_CR73","doi-asserted-by":"publisher","first-page":"13789","DOI":"10.1073\/pnas.0605944103","volume":"103","author":"E Hobeika","year":"2006","unstructured":"Hobeika E, Thiemann S, Storch B, Jumaa H, Nielsen PJ, Pelanda R, et al. Testing gene function early in the B cell lineage in mb1-cre mice. Proc Natl Acad Sci U S A. 2006;103:13789\u201394. https:\/\/doi.org\/10.1073\/pnas.0605944103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2646_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/1471-213X-1-4","author":"S Srinivas","year":"2001","unstructured":"Srinivas S, Watanabe T, Lin C-S, William CM, Tanabe Y, Jessell TM, et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol. 2001. https:\/\/doi.org\/10.1186\/1471-213X-1-4.","journal-title":"BMC Dev Biol"},{"key":"2646_CR75","doi-asserted-by":"publisher","unstructured":"D Alameda I Goicoechea M Vicari E Arriazu A Nevone S Rodriguez et al American Society of Hematology 2021 Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development Blood 138 1583 1589 https:\/\/doi.org\/10.1182\/blood.2020009754","DOI":"10.1182\/blood.2020009754"},{"key":"2646_CR76","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","volume":"29","author":"M Larrayoz","year":"2023","unstructured":"Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, et al. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nat Med. 2023;29:632\u201345. https:\/\/doi.org\/10.1038\/s41591-022-02178-3.","journal-title":"Nat Med"},{"key":"2646_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1475","volume":"2","author":"T Nojima","year":"2011","unstructured":"Nojima T, Haniuda K, Moutai T, Matsudaira M, Mizokawa S, Shiratori I, et al. In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo. Nat Commun. 2011;2:465. https:\/\/doi.org\/10.1038\/ncomms1475.","journal-title":"Nat Commun"},{"key":"2646_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12494-x","author":"R Caeser","year":"2019","unstructured":"Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, et al. Genetic modification of primary human B cells to model high-grade lymphoma. Nat Commun. 2019. https:\/\/doi.org\/10.1038\/s41467-019-12494-x.","journal-title":"Nat Commun"},{"key":"2646_CR79","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1182\/blood-2010-12-326868","volume":"117","author":"LS Hodge","year":"2011","unstructured":"Hodge LS, Novak AJ, Grote DM, Braggio E, Ketterling RP, Manske MK, et al. Establishment and characterization of a novel Waldenstr\u00f6m macroglobulinemia cell line, MWCL-1. Blood. 2011;117:e190\u20137. https:\/\/doi.org\/10.1182\/blood-2010-12-326868.","journal-title":"Blood"},{"key":"2646_CR80","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2024027496","volume":"146","author":"F Navarro","year":"2025","unstructured":"Navarro F, Lozano T, Fuentes-Garc\u00eda A, S\u00e1nchez-Moreno I, Larrayoz M, Justicia P, et al. Reprogramming glutamine metabolism enhances BCMA -car t-cell fitness and therapeutic efficacy in multiple myeloma. Blood. 2025;146:2931\u201344. https:\/\/doi.org\/10.1182\/blood.2024027496.","journal-title":"Blood"},{"key":"2646_CR81","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al. Comprehensive integration of single-cell data. Cell. 2019;177:1888-1902.e21. https:\/\/doi.org\/10.1016\/j.cell.2019.05.031.","journal-title":"Cell"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02646-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:13:28Z","timestamp":1787577208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02646-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2646"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02646-1","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All research involving human samples, data, and patients has been performed in accordance with the Declaration of Helsinki, has been approved by the corresponding ethical committees, and has been performed in accordance with the regulations of the corresponding Institutional Review Boards of the different institutions. Informed consent was obtained from patients, as detailed in the Materials and Methods section.Animal experimentation has been approved by the Ethical Committee of Animal Experimentation of the University of Navarra and by the Health Department of the Navarra Government, as detailed in the Materials and Methods section.For all research involving patients, informed consent to participate in the study has been obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.H. is an employee of F. Hoffmann-La Roche Ltd. and holds ownership of Roche stocks and patents.H.C.R. has received consulting and lecture fees from Abbvie, AstraZeneca, Vertex and Merck and research funding from AstraZeneca and Gilead Pharmaceuticals, and is co-founder of CDL Therapeutics GmbH.J.A.M.-C. has received research funding from Roche-Genentech, Bristol Myers Squibb, Janssen, Regeneron, Priothera Pharmaceuticals, Palleon Pharmaceuticals, AstraZeneca, and K36 Therapeutics, and is founder and holds stock options of MIMO Biosciences. The remaining authors have nothing to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"201"}}